Company: DMAC
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001437749-25-009696
Chunk: 46

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 46
---
 includes the following 18 companies:

| Annovis Bio, Inc.          | Applied Therapeutics, Inc.      | Athira Pharma, Inc.              |
| BioVie Inc.                | Clene Inc.                      | Fulcrum Therapeutics, Inc.       |
| Galectin Therapeutics Inc. | GlycoMimetics, Inc.             | Immunic, Inc.                    |
| Kezar Life Sciences, Inc.  | Longboard Pharmaceuticals, Inc. | Matinas BioPharma Holdings, Inc. |
| MediciNova, Inc.           | Ovid Therapeutics Inc.          | Soleno Therapeutics, Inc.        |
| Spruce BioSciences, Inc.   | Vigil Neuroscience, Inc.        | Zynerba Pharmaceuticals, Inc.    |

Data from this peer group, therefore, was considered in the compensation benchmarking process as one input in helping us determine appropriate pay levels for our executives.

Use of Consultants

The Compensation Committee has the authority to engage the services of outside experts and advisors as it deems necessary or appropriate to carry out its duties and responsibilities, and prior to doing so, assesses the independence of such experts and advisors from management. The Compensation Committee has retained Alpine Rewards, LLC to conduct executive officer and non-employee director compensation analyses every other year. Alpine Rewards, LLC did not provide any services to our Company other than those for which it was retained by the Compensation Committee.

<div align='center'>40</div>

Elements of Our Executive Compensation Program

During 2024, our executive compensation program consisted of several key elements, which are described in the table below, along with the key characteristics of, and the purpose for, each element and key 2024 changes.

| Element                         | Key Characteristics                                                                                                                                            | Purpose                                                                                                                                                                                        | Key 2024 Changes                                                                                                                                                                                                                                                                           |
| Base Salary                     
 (Fixed, Cash)                   | A fixed amount, paid in cash periodically throughout the year and reviewed annually and, if appropriate, adjusted.                                             | Provides a source of fixed income that is market competitive and reflects scope and responsibility of the position held.                                                                       | Our CEO received a base salary increase of 5% and our CFO received a base salary increase of 6%. Our CMO joined DiaMedica in January 2024 and her base salary was set at $425,000.                                                                                                         |
| Short-Term Incentive (STI)      
 (Variable, Cash)                | A variable, short-term element                                                                                                                                 
 of compensation